Amyloid Beta Antibody Dual-Specificity via CDR Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating conformational antibodies against amyloid-forming proteins, such as those associated with Alzheimer's disease, often result in antibodies that recognize either conformational or sequence specificity but not both, and require extensive screening to identify rare variants, making them inefficient for systematic generation against different sites or proteins.
Innovation Solution
A monoclonal antibody directed against amyloid beta (Aβ) peptides with a specific heavy chain variable region and light chain variable region composition, comprising complementarity determining regions (CDRs) with targeted amino acid sequences, is developed using a systematic directed evolution procedure to enhance affinity and specificity, allowing for efficient recognition of both conformational and sequence-specific epitopes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunization or directed evolution methods are used to generate conformational antibodies against amyloid-forming proteins, then antibodies with either conformational specificity or sequence specificity can be obtained, but not both simultaneously, and extensive secondary screening is required to identify rare variants
Solution Approach 1:
The antibody binding site is segmented into two functional zones: the CDR3 region provides conformational specificity through its interaction with the amyloid cross-beta structure, while the CDR1 and CDR2 regions provide sequence specificity through their interaction with linear peptide epitopes. This segmentation allows the antibody to simultaneously recognize both conformational and sequence-specific features of the amyloid protein.
Solution Approach 2:
Different complementarity determining regions are assigned different functional qualities: CDR3 is optimized for conformational recognition with high affinity for the amyloid fibril structure, while CDR1 and CDR2 are optimized for sequence-specific recognition. This local differentiation of binding characteristics enables dual-specificity antibodies that can distinguish between conformational and sequence features.
2Measurement precision
If extensive secondary screening is performed to identify rare conformational antibody variants, then antibodies with strict conformational and sequence specificity can be identified, but the process is not readily extendable to generate conformational antibodies against different sites or proteins in a systematic, efficient, and predictable manner
Solution Approach 1:
The antibody library is pre-filtered and oriented during the selection process to favor variants with the desired dual-specificity characteristics. By incorporating conformational epitope elements and sequence-specific peptide sequences into the immunogen or display system, the screening process is guided to efficiently identify rare variants with both conformational and sequence specificity without requiring exhaustive screening.
Solution Approach 2:
The selection process incorporates feedback mechanisms where binding to conformational epitopes and sequence-specific peptides is simultaneously assessed. Variants that fail to bind to either conformational or sequence-specific elements are eliminated early, providing feedback that guides the selection toward dual-specificity antibodies and reduces the complexity of subsequent screening.
Data Source
AI summary
The disclosure is directed to a monoclonal antibody. or an antigen-binding fragment thereof. directed against fibrils of amyloid beta (Aβ) peptides, as well as a method of treating and diagnosing neurodegenerative diseases using the monoclonal antibody.